Drug Shortage Report for CISPLATIN INJECTION
Report ID | 98188 |
Drug Identification Number | 02403188 |
Brand name | CISPLATIN INJECTION |
Common or Proper name | CISPLATIN INJECTION |
Company Name | TEVA CANADA LIMITED |
Active Ingredient(s) | CISPLATIN |
Strength(s) | 1.0MG |
Dosage form(s) | SOLUTION |
Route of administration | INTRAVENOUS |
Packaging size | 50 & 100ml |
ATC code | L01XA |
ATC description | OTHER ANTINEOPLASTIC AGENTS |
Reason for shortage | Demand increase for the drug. |
Anticipated start date | |
Actual start date | 2019-11-07 |
Estimated end date | 2020-01-31 |
Actual end date | |
Shortage status | Actual shortage |
Updated date | 2019-11-29 |
Company comments | Teva is allocating and covering 30% of the market |
Health Canada comments | |
Contact Address | 30 NOVOPHARM COURT TORONTO, ONTARIO CANADA M1B 2K9 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.